tirzepatide weight loss in one month 6 months. powerful transformation. 💪 Thanks to Compound + commitment, the results speak for themselves. Not just lost—confidence gained, energy restored, life upgraded. #TirzepatideResults #6MonthJourney #TransformationTuesday Weight loss results after 8

L- L- , ,

Leading participants such as Novo Nordisk Philippines, Inc., Sanofi Philippines, AstraZeneca Pharmaceuticals (Philippines), Inc., Merck Sharp & Dohme (MSD) Philippines, Eli Lilly Philippines, Inc., Boehringer Ingelheim (Philippines), Inc., Pfizer Philippines, Inc., GlaxoSmithKline Philippines Inc., Amgen Philippines Inc., Bayer Philippines Inc., Takeda Healthcare Philippines Inc., Johnson & Johnson (Philippines), Inc., Novartis Healthcare Philippines, Inc., Roche (Philippines) Inc., Sandoz Philippines Inc

Patients taking insulin or sulfonylureas alongside GLP-1 therapy should monitor for hypoglycaemia when reducing sugar intake and seek medication review as needed

Lifestyle modification success significantly impacts treatment duration decisions

For comparison, Semaglutide (which is Novos active ingredient for Ozempic and Wegovy) only targets the GLP-1 receptor